Pembrolizumab Biosimilar(Prestige BioPharma)

帕博利珠单抗生物类似药(Prestige BioPharma)

Report date: 2025/02/18 10:50:02

Base Information

Drug NamePembrolizumab Biosimilar(Prestige BioPharma)
Drug Alias NamePBP2102PBP-2102
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 antagonists
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPrestige BioPharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPrestige BioPharma Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A